Table 1 Demographic and clinical characteristics of the study participants
Variables | IMPRESS Total participants n = 90 | IMPRESS TB/HIV positive n = 60 | IMPRESS TB positive and HIV negative n = 30 | CAPRISA 002 HIV positive n = 19 | Healthy Donors n = 11 |
|---|---|---|---|---|---|
Randomization arm n (%) | |||||
 HRZE—Control | 43 (48.0) | 28 (47.0) | 15 (50.0) | - | - |
 HRZM—Active | 47 (52.0) | 32 (53.0) | 15 (50.0) | - | - |
Age (y), median (IQR) | 34.5 (29.0 – 41.5) | 35.0 (31 – 40.7) | 33.0 (24.0 – 50.5) | 33.0 (29.0 – 36.0) | 34.0 (32.0 – 40.0) |
Gender, n (%) | |||||
 Male | 68 (76.0) | 42 (70.0) | 26 (87.0) | - | 5 (45.0) |
 Female | 22 (24.0) | 18 (30.0) | 4 (13.0) | 19 (100.0) | 6 (55.0) |
Body mass index (kg/m2), mean (IQR) | 20.6 (18.2 – 21.8) | 20.5 (17.9 – 22.3) | 20.9 (18.4 – 21.5) | 32.9 (30.5 – 35.9) | 24.7 (19.7 – 31.3)a |
CD4 cell count (cells/mm3), mean (IQR) | 303.0 (150.0 – 446.0) | 303.0 (150.0 – 446.0) | - | 551.0 (361.0 – 717.0) | - |
HIV viral load (copies/ml), mean (IQR) | 94,907.0 (20.0 – 60,744.0) | 94,907.0 (20.0 – 60,744.0) | - | 56,399.0 (998.0 – 95,212.0)c | - |
ART status n (%) | |||||
 Yes | 33 (50.0) | 30 (50.0) | - | 11 (58.0) | - |
 No | 27 (45.0) | 27 (45.0) | - | 8 (42.0) | - |
Time on ART (months), median (IQR) | 1.0 (0.0 – 36.0) | 1.0 (0.0 – 36.0) | - | 5 .0(0.0 – 46.0) | - |
Lung Cavities n (%) | |||||
 None | 25 (28.0) | 21 (35.0) | 4 (13.0) | - | - |
 One Lung | 38 (42.0) | 25 (42.0) | 13 (43.0) | - | - |
 Both Lungs | 27 (30.0) | 14 (23.0) | 13 (43.0) | - | - |
Days to first negative solid culture, median (IQR)b | 54.0 (28.0 – 79.8) | 44.0 (28.0 – 79.8) | 56.0 (42.0 – 82.3) | - | - |
Alcohol Use in the past 3Â months n (%) | |||||
 Yes | 29 (32.0) | 22 (37.0) | 7 (23.0) | - | - |
Smoking in past 3Â months n (%) | Â | Â | |||
 Yes | 35 (39.0) | 21 (35.0) | 14 (47.0) | - | - |